Reports Q3 revenue $67.455M, consensus $72.81M. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, “We continued to see revenue growth with significant gross margin improvement in the third quarter of 2025. Amtagvi demand is increasing as we integrate our community treatment centers to drive earlier treatment and better outcomes for patients. We are building a successful commercial business, while advancing our high value development programs to address significant unmet medical needs in patients with solid tumor cancers.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- IOVA Earnings this Week: How Will it Perform?
- Iovance Biotherapeutics’ Lifileucel Therapy: Promising Developments and Market Potential Justify Buy Rating
- Iovance Biotherapeutics reports clinical data from Phase 2 IOV-LUN-202 trial
- Iovance Biotherapeutics price target lowered to $9 from $20 at H.C. Wainwright
- Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study